Funding for this research was provided by:
Text and Data Mining valid from 2018-09-24
Received: 21 December 2017
Accepted: 18 September 2018
First Online: 24 September 2018
Ethics approval and consent to participate
: This study was approved by The University of Texas MD Anderson Cancer Center Institutional Review Board (IRB; IRB reference number 2017–0143) and will be conducted in agreement with the requirements of the Code of Federal Regulations and the Institutional Review Board. All patients will be required to sign an IRB-approved consent form, indicating their agreement to participate. The consent form includes the nature, objectives, and potential risks and benefits of the study and details the required length of follow-up, required tissue biopsies and blood sample collections, supportive care, the name of the principal investigator (CLR) responsible for the protocol. The consent additionally specifies the patient’s right to accept or refuse treatment and to terminate participation and withdraw from the protocol. All data collection with be performed in accordance with the human subjects research policies of MD Anderson Cancer Center.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.